Research Article
Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients
Table 2
Primary and secondary endpoints.
| Primary endpoint: | | Incidence of severe hepatotoxicity | 10.7% (6/56 Patients) | Secondary endpoints | | NNRTIs | 3 cases/1203 months | | 0.249 cases per 100 months of exposure | Efavirenz | 2 cases/923 months | | 0.217 cases per 100 months of exposure | Nevirapine | 1 case/280 months | | 0.357 cases per 100 months of exposure | PIs | 3 cases/996 months | | 0.301 cases per 100 months of exposure | Indinavir | 1 case/97 months | | 1.03 cases per 100 months of exposure | Nelfinavir | 1 case/169 months | | 0.592 cases per 100 months of exposure | Saquinavir/Ritonavir | 1 case/100 months | | 1.00 cases per 100 months of exposure |
|
|